TARA insider transaction filings
Protara Therapeutics, Inc. — 49 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-01. Screen TARA transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-01 | 4 | Shefferman Jesse — CEO and President, Director | Option exercise (M): 215,687 @ $1.91 · Sale (S): 215,687 @ $4.09 · Gift (G): 14,000 @ $0 · Gift (G): 7,000 @ $0 · Gift (G): 4,000 @ $0 · Gift (G): 5,000 @ $0 · +1 more | EDGAR |
| 2026-06-16 | 4 | Levy Richard S — Director | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Solomon Michael Edward — Director | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Smith Cynthia — Director | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Huang Jane — Director | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | GARCEAU ROGER — Director | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Flannelly Barry P — Director | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | SARGEN GREGORY — Director | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | BESHAR LUKE M — Director | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | CONKLING WILLIAM — Chief Commercial Officer | Tax withholding (F): 6,008 @ $4.34 | EDGAR |
| 2026-04-09 | 4 | Zummo Jacqueline — Chief R&D Officer | Sale (S): 1,134 @ $5.40 | EDGAR |
| 2026-04-02 | 4 | Zummo Jacqueline — Chief R&D Officer | Sale (S): 22,598 @ $5.26 | EDGAR |
| 2026-01-27 | 4 | Shefferman Jesse — CEO and President, Director | Tax withholding (F): 8,732 @ $6.67 | EDGAR |
| 2026-01-27 | 4 | Zummo Jacqueline — Chf Scientific Operations Off | Tax withholding (F): 3,724 @ $6.67 | EDGAR |
| 2026-01-27 | 4 | Fry Hannah — VP, Controller | Tax withholding (F): 1,457 @ $6.67 | EDGAR |
| 2026-01-27 | 4 | Fabbio Patrick — Chief Financial Officer | Tax withholding (F): 3,261 @ $6.67 | EDGAR |
| 2026-01-22 | 4 | Shefferman Jesse — CEO and President, Director | Tax withholding (F): 16,322 @ $5.60 | EDGAR |
| 2026-01-22 | 4 | Fabbio Patrick — Chief Financial Officer | Tax withholding (F): 3,063 @ $5.60 | EDGAR |
| 2026-01-22 | 4 | Zummo Jacqueline — Chf Scientific Operations Off | Tax withholding (F): 6,578 @ $5.60 | EDGAR |
| 2026-01-22 | 4 | Fry Hannah — VP, Controller | Tax withholding (F): 2,132 @ $5.60 | EDGAR |
| 2026-01-21 | 4 | CONKLING WILLIAM — Chief Commercial Officer | Grant/award (A): 26,000 @ $0 · Grant/award (A): 158,000 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Fabbio Patrick — Chief Financial Officer | Grant/award (A): 28,000 @ $0 · Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Fry Hannah — VP, Controller | Grant/award (A): 9,500 @ $0 · Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Nicacio Leonardo Viana — Chief Medical Officer | Grant/award (A): 26,000 @ $0 · Grant/award (A): 158,000 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Shefferman Jesse — CEO and President, Director | Grant/award (A): 87,000 @ $0 · Grant/award (A): 524,000 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Zummo Jacqueline — Chf Scientific Operations Off | Grant/award (A): 30,000 @ $0 · Grant/award (A): 180,000 (derivative) @ $0 | EDGAR |
| 2025-07-07 | 4 | Shefferman Jesse — CEO and President, Director | Gift (G): 300,000 @ $0 | EDGAR |
| 2025-06-30 | 4 | Shefferman Jesse — CEO and President, Director | Gift (G): 1,700 @ $0 · Gift (G): 3,400 @ $0 · Gift (G): 10,200 @ $0 · Gift (G): 3,367 @ $0 | EDGAR |
| 2025-06-13 | 4 | Solomon Michael Edward — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Smith Cynthia — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Levy Richard S — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Huang Jane — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | GARCEAU ROGER — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Flannelly Barry P — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | SARGEN GREGORY — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | BESHAR LUKE M — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | CONKLING WILLIAM — Chief Commercial Officer | Grant/award (A): 50,000 @ $0 · Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4/A | Levy Richard S — Director | Purchase (P): 20,000 @ $3.19 | EDGAR |
| 2025-05-16 | 4 | Levy Richard S — Director | Purchase (P): 20,000 @ $3.19 | EDGAR |
| 2025-04-17 | 4 | Nicacio Leonardo Viana — Chief Medical Officer | Grant/award (A): 50,000 @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-03-28 | 4 | Zummo Jacqueline — Chf Scientific Operations Off | Sale (S): 21,224 @ $4.53 | EDGAR |
| 2025-03-28 | 4/A | Fabbio Patrick — Chief Financial Officer | Holdings only — no transactions reported | EDGAR |
| 2025-03-28 | 4/A | Shefferman Jesse — CEO and President, Director | Holdings only — no transactions reported | EDGAR |
| 2025-03-28 | 4/A | Fry Hannah — VP, Controller | Holdings only — no transactions reported | EDGAR |
| 2025-03-28 | 4/A | Zummo Jacqueline — Chf Scientific Operations Off | Holdings only — no transactions reported | EDGAR |
| 2025-01-28 | 4 | Shefferman Jesse — CEO and President, Director | Grant/award (A): 65,000 @ $0 · Grant/award (A): 387,000 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Zummo Jacqueline — Chf Scientific Operations Off | Grant/award (A): 24,500 @ $0 · Grant/award (A): 146,000 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Fry Hannah — VP, Controller | Grant/award (A): 9,500 @ $0 · Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Fabbio Patrick — Chief Financial Officer | Grant/award (A): 23,500 @ $0 · Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Protara Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-15 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-30 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2026-03-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-24 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-15 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-03 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TARA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →